Cellebrite DI (NASDAQ:CLBT) Trading 7.1% Higher – Should You Buy?

Cellebrite DI Ltd. (NASDAQ:CLBT)’s stock price traded up 7.1% during mid-day trading on Thursday . The stock traded as high as $15.15 and last traded at $15.1670. 1,096,592 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 1,895,732 shares. The stock had previously closed at $14.16.

Wall Street Analyst Weigh In

A number of analysts recently commented on CLBT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Needham & Company LLC decreased their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Wall Street Zen downgraded shares of Cellebrite DI from a “hold” rating to a “sell” rating in a report on Saturday. Bank of America boosted their price objective on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Finally, Lake Street Capital upped their price objective on shares of Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.50.

Cellebrite DI Price Performance

The firm’s 50-day moving average price is $15.61 and its 200-day moving average price is $16.94. The company has a market cap of $3.82 billion, a price-to-earnings ratio of 49.35, a price-to-earnings-growth ratio of 2.33 and a beta of 1.30.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, meeting the consensus estimate of $0.14. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. The business had revenue of $128.82 million for the quarter, compared to analyst estimates of $126.07 million. During the same quarter in the previous year, the business posted $0.10 EPS. The business’s quarterly revenue was up 28.8% on a year-over-year basis. On average, sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Institutional Investors Weigh In On Cellebrite DI

Several institutional investors and hedge funds have recently modified their holdings of CLBT. Y.D. More Investments Ltd raised its stake in shares of Cellebrite DI by 76.2% during the second quarter. Y.D. More Investments Ltd now owns 441,579 shares of the company’s stock valued at $7,065,000 after purchasing an additional 191,020 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Cellebrite DI by 40.4% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 359,764 shares of the company’s stock valued at $6,652,000 after purchasing an additional 103,568 shares during the period. Norwood Investment Partners LP purchased a new position in shares of Cellebrite DI in the third quarter valued at $4,274,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Cellebrite DI during the 3rd quarter valued at $19,457,000. Finally, Moody National Bank Trust Division purchased a new stake in Cellebrite DI during the 3rd quarter worth $2,670,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.